{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:28:47Z","timestamp":1789086527294,"version":"build-2803163510"},"reference-count":18,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2008,7,21]],"date-time":"2008-07-21T00:00:00Z","timestamp":1216598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES<\/jats:title>\n                    <jats:p>To assess the utility of perceived control over ejaculation (\u2018control\u2019) in the evaluation of treatment benefit in men with premature ejaculation (PE), and to compare effects associated with a two\u2010category or greater increase in this variable between men receiving dapoxetine and placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      This subanalysis used combined data from all treatment groups in an integrated analysis of two identically designed, 12\u2010week, double\u2010blind, randomized, placebo\u2010controlled trials of dapoxetine. Men (2614) met the\n                      <jats:italic>Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic>\n                      (fourth edition, text revision) criteria for PE, had a stopwatch\u2010measured intravaginal ejaculatory latency time (IELT) of \u22642\u2003min in \u226575% of events in a 2\u2010week baseline period, and self\u2010reported moderate or severe PE. Men received placebo or dapoxetine 30 or 60\u2003mg, 1\u20133\u2003h before intercourse. The stopwatch\u2010measured IELT was recorded for each episode; the patient\u2010reported global impression of change (PGI; 7\u2010point scale, \u2018much worse\u2019 to \u2018much better\u2019), control and satisfaction with sexual intercourse (5\u2010point scales, \u2018very poor\u2019 to \u2018very good\u2019) were assessed monthly. The utility of a two\u2010category or greater increase in control was evaluated by examining the relationship of this variable with IELT and satisfaction with sexual intercourse.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Of 2341 men with baseline and endpoint assessments, 96.8% reported \u2018very poor\u2019 or \u2018poor\u2019 control at baseline, and 748 (32%) reported a two\u2010category or greater increase in control after treatment. More than 95% of those men rated their PE as \u2018slightly better\u2019, \u2018better\u2019, or \u2018much better\u2019 on the PGI; 67.1% gave ratings of \u2018better\u2019 or \u2018much better.\u2019 They also had greater improvements in IELT than men with less than a two\u2010category increase in control, with a mean (\n                      <jats:sc>sd<\/jats:sc>\n                      ) change from baseline of 3.7\u2003(4.3) vs 0.77\u2003(1.8)\u2003min, respectively, and a greater percentage reported good or very good satisfaction with sexual intercourse than men with less than a two\u2010category increase in control (74% vs 19%, respectively). Nausea, headache and upper respiratory tract infection were the most common adverse events reported by men with a two\u2010category or greater increase in control (15.8%, 7.4% and 6.6%, respectively) and those without (8.5%, 5.5% and 6.5%, respectively). The proportions of men with a two\u2010category or greater increase in control with dapoxetine 30 and 60\u2003mg were 36.3% and 44.5%, respectively (vs 15% with placebo).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>A two\u2010category or greater increase in control (5\u2010point scale) is useful for assessing the treatment benefit in men with PE; it corresponds with improvements in the man\u2019s perception of his condition, substantially greater prolongation of IELT, and higher levels of satisfaction with sexual intercourse.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2008.07845.x","type":"journal-article","created":{"date-parts":[[2008,7,21]],"date-time":"2008-07-21T13:09:15Z","timestamp":1216645755000},"page":"824-828","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine"],"prefix":"10.1111","volume":"102","author":[{"given":"Ridwan","family":"Shabsigh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Bull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fisseha","family":"Tesfaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,9]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.07.004"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.6.537"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2005.20353.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.10.025"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00464.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2004.10109.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199808000-00004"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2605.2006.00689.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2006.00424.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000195110.79027.3f"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.09.002"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901172"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69373-2"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000132159.61156.ea"},{"key":"e_1_2_8_17_2","unstructured":"National Center for Health Statistics.International Classification of Diseases Ninth Revision Clinical Modifications (ICD\u20109\u2010CM).Available at:http:\/\/www.cdc.gov\/nchs\/about\/otheract\/icd9\/abticd9.htm"},{"key":"e_1_2_8_18_2","volume-title":"FDA Guidance for Industry: Patient\u2010Reported Outcome Measures: Use in Medicinal Product Development to Support Labeling Claims.","author":"United States Food and Drug Administration.","year":"2006"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.10.044"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2008.07845.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2008.07845.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:06:44Z","timestamp":1761736004000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2008.07845.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1111\/j.1464-410X.2008.07845.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2008.07845.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"2008-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}